The German biotech firm finds itself at the intersection of several high-stakes developments. A Munich court has handed the company a patent victory over rival Promosome, just as it negotiates the sale of production sites slated for closure to a former competitor. Meanwhile, the founders who turned BioNTech into a household name are preparing to bow out by the end of next year. The stock, for its part, has barely budged — caught in a sideways drift that mirrors the uncertainty surrounding each of these moving parts.
Court Victory But No Knockout
The Unified Patent Court in Munich struck down a disputed mRNA patent held by US biotech Promosome, ruling it invalid for Germany, France and Sweden. Promosome had standing to sue under Article 47(2) of the UPC Agreement, having secured an exclusive licence, but the court rejected its case on two fronts: the patent lacked novelty, and even if it had been valid, Promosome could not prove BioNTech and its partner Pfizer had infringed it. The experiments Promosome submitted failed to show the required alterations to secondary start codons — the observed increase in protein production could just as easily be explained by classic codon optimisation.
It remains unclear whether Promosome will appeal. The company has a history of retreat: it withdrew a parallel lawsuit against BioNTech and Pfizer in a California federal court last October, doing so with prejudice, meaning the case cannot be refiled. Comirnaty continues to face patent challenges from other players — Moderna and CureVac have already attacked the vaccine across Europe, and GSK took all three parties to the UPC last summer.
Moderna Circles BioNTech’s Idle Factories
Alongside the courtroom success, BioNTech is pursuing an exit from much of its German manufacturing footprint. In June, the company announced plans to close three domestic sites — Idar-Oberstein, Marburg and Tübingen — plus a plant in Singapore by the end of 2027. Some 1,860 jobs are at stake across those locations. A fourth closure involves JPT Peptide Technologies, a subsidiary acquired in 2009 that is no longer profitable; BioNTech expects to wind down that unit by the end of 2026, affecting up to another 140 positions.
Those shuttered factories have attracted a surprising suitor. Moderna CEO Stéphane Bancel confirmed to Handelsblatt that his company is interested in taking over the German sites, a move he described as pragmatic. Rather than building new capacity in Germany, Moderna would snap up existing facilities — and likely hire some of the BioNTech staff currently facing redundancy. But the deal is conditional on the German government’s support, and Berlin’s planned healthcare reforms have already spooked other drugmakers. Eli Lilly and Boehringer Ingelheim have shelved expansion plans in the country as a result.
BioNTech hopes the restructuring will generate recurring annual savings of roughly €500 million from 2029 onward, cash it plans to channel into its oncology pipeline. For the vacant factories, the company is also exploring a full or partial sale.
Should investors sell immediately? Or is it worth buying BioNTech?
The Founders’ Exit Looms
Perhaps the most profound shift in BioNTech’s corporate identity comes from the top. Co-founders Ugur Sahin and Özlem Türeci will step down by the end of 2026 to launch a new company focused on next-generation mRNA innovations. The supervisory board has already begun searching for successors. A leadership change of this magnitude during a broad operational overhaul is unusual and will keep investors on edge as the search progresses.
Acquisition Progress and a Stretched Balance Sheet
BioNTech’s takeover of CureVac is nearing completion. CureVac shareholders approved the exchange offer with a majority exceeding 99%, and Germany’s Federal Cartel Office has cleared the deal, removing the final regulatory hurdles. The purchase is intended to strengthen BioNTech’s mRNA technology platform.
The financial picture is under pressure. For 2025, BioNTech reported revenue of €2.9 billion but a net loss that ballooned to €1.136 billion, up from €665 million a year earlier. Management forecasts 2026 revenue of between €2.0 billion and €2.3 billion, implying a further decline. Despite the losses, the company has launched a share buyback of up to $1 billion over the next twelve months, drawing on its deep cash reserves: €17.2 billion in cash and securities sat on the books at the end of December 2025.
Stock Drifts as Investors Weigh the Outlook
The shares closed the week at €80.20, sliding 1.41% on Friday alone and leaving a weekly loss of 4.86%. Over 30 days, however, the stock has recovered 7.36%. Year to date it is down 2.79%, and over the past twelve months the decline stands at 17.66%.
Technically, the stock sits just above its 50-day moving average of €79.38 but well below the 200-day average of €85.13 — a gap that suggests near-term stability but persistent longer-term pressure. The relative strength index of 48.5 points to neutral territory, neither overbought nor oversold, while annualised volatility remains elevated at around 29%. From the January high of €105.80 the stock is still 24.20% off the peak, though it retains a 17.34% cushion above the March low of €68.35.
Two big unknowns now occupy the minds of BioNTech watchers: will Promosome appeal the Munich ruling, and can Moderna strike a deal with Berlin to buy the German factories? The answers will help determine whether the operational environment truly begins to ease — or remains as tangled as the share price suggests.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from July 11 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 11.
BioNTech: Buy or sell? Read more here...
